Insomnia Market (Treatment Type: Benzodiazepines, Nonbenzodiazepines, Antidepressants, Orexin Antagonist, Melatonin Antagonist, Devices, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2023-2031

Insomnia Market (Treatment Type: Benzodiazepines, Nonbenzodiazepines, Antidepressants, Orexin Antagonist, Melatonin Antagonist, Devices, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2023-2031


Insomnia Market – Scope of Report

TMR’s report on the global insomnia market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global insomnia market for the period 2017–2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global insomnia market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the insomnia market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global insomnia market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global insomnia market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global insomnia market.

The report delves into the competitive landscape of the global insomnia market. Key players operating in the global insomnia market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global insomnia market profiled in this report.

Key Questions Answered in Global insomnia Market Report
  • What is the sales/revenue generated by insomnia across all regions during the forecast period?
  • What are the opportunities in the global insomnia market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2031?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?
Insomnia Market – Research Objectives and Research Approach

The comprehensive report on the global insomnia market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global insomnia market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global insomnia market.


1. Executive Summary
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Insomnia Market
4. Market Overview
4.1. Market Segmentation
4.1.1. Segment Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Insomnia Market Analysis and Forecasts, 2017-2031
5. Key Insights
5.1. Pipeline Analysis
5.2. Disease Prevalence & Incidence Rate Globally with Key Countries
5.3. COVID-19 Pandemic Impact on Industry
6. Insomnia Market Analysis and Forecast, by Treatment Type
6.1. Introduction and Definitions
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Treatment Type, 2017–2031
6.3.1. Benzodiazepines
6.3.2. Nonbenzodiazepines
6.3.3. Antidepressants
6.3.4. Orexin Antagonist
6.3.5. Melatonin Antagonist
6.3.6. Devices
6.3.7. Others
6.4. Market Attractiveness, by Treatment Type
7. Global Insomnia Market Analysis and Forecast, by Sales Channel
7.1. Introduction and Definitions
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Sales Channel, 2017–2031
7.3.1. Hospital Pharmacies
7.3.2. Retail Pharmacies and Drug Stores
7.3.3. Online Pharmacies
7.4. Market Attractiveness, by Sales Channel
8. Global Insomnia Market Analysis and Forecast, by Region
8.1. Key Findings
8.2. Market Value Forecast, by Region, 2017–2031
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. Market Attractiveness, by Region
9. North America Insomnia Market Analysis and Forecast
9.1. Introduction
9.1.1. Key Findings
9.2. Market Value Forecast, by Treatment Type, 2017–2031
9.2.1. Benzodiazepines
9.2.2. Nonbenzodiazepines
9.2.3. Antidepressants
9.2.4. Orexin Antagonist
9.2.5. Melatonin Antagonist
9.2.6. Devices
9.2.7. Others
9.3. Market Value Forecast, by Sales Channel, 2017–2031
9.3.1. Hospital Pharmacies
9.3.2. Retail Pharmacies and Drug Stores
9.3.3. Online Pharmacies
9.4. Market Value Forecast, by Country, 2017–2031
9.4.1. U.S.
9.4.2. Canada
9.5. Market Attractiveness Analysis
9.5.1. By Treatment Type
9.5.2. By Sales Channel
9.5.3. By Country
10. Europe Insomnia Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Treatment Type, 2017–2031
10.2.1. Benzodiazepines
10.2.2. Nonbenzodiazepines
10.2.3. Antidepressants
10.2.4. Orexin Antagonist
10.2.5. Melatonin Antagonist
10.2.6. Devices
10.2.7. Others
10.3. Market Value Forecast, by Sales Channel, 2017–2031
10.3.1. Hospital Pharmacies
10.3.2. Retail Pharmacies and Drug Stores
10.3.3. Online Pharmacies
10.4. Market Value Forecast, by Country/Sub-region, 2017–2031
10.4.1. Germany
10.4.2. U.K.
10.4.3. France
10.4.4. Italy
10.4.5. Spain
10.4.6. Rest of Europe
10.5. Market Attractiveness Analysis
10.5.1. By Treatment Type
10.5.2. By Sales Channel
10.5.3. By Country/Sub-region
11. Asia Pacific Insomnia Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Treatment Type, 2017–2031
11.2.1. Benzodiazepines
11.2.2. Nonbenzodiazepines
11.2.3. Antidepressants
11.2.4. Orexin Antagonist
11.2.5. Melatonin Antagonist
11.2.6. Devices
11.2.7. Others
11.3. Market Value Forecast, by Sales Channel, 2017–2031
11.3.1. Hospital Pharmacies
11.3.2. Retail Pharmacies and Drug Stores
11.3.3. Online Pharmacies
11.4. Market Value Forecast, by Country/Sub-region, 2017–2031
11.4.1. China
11.4.2. Japan
11.4.3. India
11.4.4. Australia & New Zealand
11.4.5. Rest of Asia Pacific
11.5. Market Attractiveness Analysis
11.5.1. By Treatment Type
11.5.2. By Sales Channel
11.5.3. By Country/Sub-region
12. Latin America Insomnia Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Treatment Type, 2017–2031
12.2.1. Benzodiazepines
12.2.2. Nonbenzodiazepines
12.2.3. Antidepressants
12.2.4. Orexin Antagonist
12.2.5. Melatonin Antagonist
12.2.6. Devices
12.2.7. Others
12.3. Market Value Forecast, by Sales Channel, 2017–2031
12.3.1. Hospital Pharmacies
12.3.2. Retail Pharmacies and Drug Stores
12.3.3. Online Pharmacies
12.4. Market Value Forecast, by Country/Sub-region, 2017–2031
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Rest of Latin America
12.5. Market Attractiveness Analysis
12.5.1. By Treatment Type
12.5.2. By Sales Channel
12.5.3. By Country/Sub-region
13. Middle East & Africa Insomnia Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Treatment Type, 2017–2031
13.2.1. Benzodiazepines
13.2.2. Nonbenzodiazepines
13.2.3. Antidepressants
13.2.4. Orexin Antagonist
13.2.5. Melatonin Antagonist
13.2.6. Devices
13.2.7. Others
13.3. Market Value Forecast, by Sales Channel, 2017–2031
13.3.1. Hospital Pharmacies
13.3.2. Retail Pharmacies and Drug Stores
13.3.3. Online Pharmacies
13.4. Market Value Forecast, by Country/Sub-region, 2017–2031
13.4.1. GCC Countries
13.4.2. South Africa
13.4.3. Rest of Middle East & Africa
13.5. Market Attractiveness Analysis
13.5.1. By Treatment Type
13.5.2. By Sales Channel
13.5.3. By Country/Sub-region
14. Competition Landscape
14.1. Market Player – Competition Matrix (By Tier and Size of Companies)
14.2. Market Share Analysis, by Company (2022)
14.3. Company Profiles
14.3.1. Paratek Pharmaceuticals, Inc.
14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.1.2. Treatment Type Portfolio
14.3.1.3. Financial Overview
14.3.1.4. SWOT Analysis
14.3.1.5. Strategic Overview
14.3.2. Sumitomo Dainippon Pharma Co., Ltd.
14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.2.2. Treatment Type Portfolio
14.3.2.3. Financial Overview
14.3.2.4. SWOT Analysis
14.3.2.5. Strategic Overview
14.3.3. Teva Pharmaceutical Industries Limited
14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.3.2. Treatment Type Portfolio
14.3.3.3. Financial Overview
14.3.3.4. SWOT Analysis
14.3.3.5. Strategic Overview
14.3.4. Vanda Pharmaceuticals Inc.
14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.4.2. Treatment Type Portfolio
14.3.4.3. Financial Overview
14.3.4.4. SWOT Analysis
14.3.4.5. Strategic Overview
14.3.5. Takeda Pharmaceutical Company Limited
14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.5.2. Treatment Type Portfolio
14.3.5.3. Financial Overview
14.3.5.4. SWOT Analysis
14.3.5.5. Strategic Overview
14.3.6. Pfizer Inc.
14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.6.2. Treatment Type Portfolio
14.3.6.3. Financial Overview
14.3.6.4. SWOT Analysis
14.3.6.5. Strategic Overview
14.3.7. Sanofi S.A
14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.7.2. Treatment Type Portfolio
14.3.7.3. Financial Overview
14.3.7.4. SWOT Analysis
14.3.7.5. Strategic Overview
14.3.8. Merck & Co., Inc.
14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.8.2. Treatment Type Portfolio
14.3.8.3. Financial Overview
14.3.8.4. SWOT Analysis
14.3.8.5. Strategic Overview
14.3.9. Viatris Inc.
14.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.9.2. Treatment Type Portfolio
14.3.9.3. Financial Overview
14.3.9.4. SWOT Analysis
14.3.9.5. Strategic Overview

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings